{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:26:29Z","timestamp":1792110389934,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejca.2021.08.036","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:36:46Z","timestamp":1634085406000},"page":"474-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"C","title":["Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6729-6200","authenticated-orcid":false,"given":"Marie","family":"Kostine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Mauric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Tison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0975-8534","authenticated-orcid":false,"given":"Thomas","family":"Barnetche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Barre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-577X","authenticated-orcid":false,"given":"Macha","family":"Nikolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Rouxel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-5736","authenticated-orcid":false,"given":"L\u00e9a","family":"Dousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0272-2640","authenticated-orcid":false,"given":"Sorilla","family":"Prey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-1229","authenticated-orcid":false,"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-0908","authenticated-orcid":false,"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Veillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Vergnenegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5621-812X","authenticated-orcid":false,"given":"Amaury","family":"Daste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9455-0657","authenticated-orcid":false,"given":"Charlotte","family":"Domblides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Sionneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Gross-Goupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-6744","authenticated-orcid":false,"given":"Alain","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2021.08.036_bib1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"7420","key":"10.1016\/j.ejca.2021.08.036_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature11489","article-title":"Cancer therapy: tumours switch to resist","volume":"490","author":"Ribas","year":"2012","journal-title":"Nature"},{"issue":"6264","key":"10.1016\/j.ejca.2021.08.036_bib3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"issue":"6264","key":"10.1016\/j.ejca.2021.08.036_bib4","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.ejca.2021.08.036_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ejca.2021.08.036_bib6","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2021.08.036_bib7","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ejca.2021.08.036_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00262-019-02453-2","article-title":"The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies","volume":"69","author":"Wilson","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"16","key":"10.1016\/j.ejca.2021.08.036_bib9","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1158\/0008-5472.CAN-16-0448","article-title":"Fine-tuning cancer immunotherapy: optimizing the gut microbiome","volume":"76","author":"Pitt","year":"2016","journal-title":"Cancer Res"},{"issue":"6371","key":"10.1016\/j.ejca.2021.08.036_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1126\/science.aar2946","article-title":"Precision medicine using microbiota","volume":"359","author":"Jobin","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejca.2021.08.036_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-micro-091313-103456","article-title":"Effects of antibiotics on human microbiota and subsequent disease","volume":"68","author":"Keeney","year":"2014","journal-title":"Annu Rev Microbiol"},{"issue":"24","key":"10.1016\/j.ejca.2021.08.036_bib12","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1111\/bph.14366","article-title":"Drug-gut microbiota interactions: implications for neuropharmacology","volume":"175","author":"Walsh","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejca.2021.08.036_bib13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.mib.2017.11.001","article-title":"Systematically investigating the impact of medication on the gut microbiome","volume":"39","author":"Maier","year":"2017","journal-title":"Curr Opin Microbiol"},{"issue":"5","key":"10.1016\/j.ejca.2021.08.036_bib14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.ejca.2021.08.036_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2021.08.036_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1568812","article-title":"Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors","volume":"8","author":"Elkrief","year":"2019","journal-title":"Oncoimmunology"},{"issue":"28","key":"10.1016\/j.ejca.2021.08.036_bib17","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2021.08.036_bib18","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Brief report: early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2021.08.036_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2017.10.009","article-title":"Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: a systematic review","volume":"120","author":"Garant","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.ejca.2021.08.036_bib20","doi-asserted-by":"crossref","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2021.08.036_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2020.09.033","article-title":"Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index","volume":"142","author":"Buti","year":"2020","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2021.08.036_bib22","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/1078-0432.CCR-18-2748","article-title":"Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043\/62072 trials","volume":"25","author":"Mir","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.08.036_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.10.031","article-title":"High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients","volume":"144","author":"Cantini","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2021.08.036_bib24","first-page":"137","article-title":"Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: an observational study","volume":"10","author":"Omori","year":"2019","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.08.036_bib25","doi-asserted-by":"crossref","first-page":"1836766","DOI":"10.1080\/2162402X.2020.1836766","article-title":"Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1\/PD-L1 immune checkpoint blockers","volume":"9","author":"Medjebar","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ejca.2021.08.036_bib26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40425-018-0375-1","article-title":"Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1\/anti-CTLA-4) in metastatic malignant melanoma","volume":"6","author":"Afzal","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2021.08.036_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","article-title":"Role of the microbiota in immunity and inflammation","volume":"157","author":"Belkaid","year":"2014","journal-title":"Cell"},{"issue":"6391","key":"10.1016\/j.ejca.2021.08.036_bib28","first-page":"360","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"25","author":"Ma","year":"2018","journal-title":"Science"},{"issue":"7741","key":"10.1016\/j.ejca.2021.08.036_bib29","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","article-title":"A defined commensal consortium elicits CD8 T cells and anti-cancer immunity","volume":"565","author":"Tanoue","year":"2019","journal-title":"Nature"},{"issue":"6529","key":"10.1016\/j.ejca.2021.08.036_bib30","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"issue":"6529","key":"10.1016\/j.ejca.2021.08.036_bib31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejca.2021.08.036_bib32","article-title":"Lactobacillus rhamnosus GG induces cGAS\/STING- dependent type I interferon and improves response to immune checkpoint blockade","author":"Si","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2021.08.036_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejca.2020.07.026","article-title":"Role of the gut microbiome for cancer patients receiving immunotherapy: dietary and treatment implications","volume":"138","author":"Lee","year":"2020","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2021.08.036_bib34","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.4049\/jimmunol.1900594","article-title":"Cutting edge: targeting thrombocytes to rewire anticancer immunity in the tumor microenvironment and potentiate efficacy of PD-1 blockade","volume":"203","author":"Riesenberg","year":"2019","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.ejca.2021.08.036_bib35","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","article-title":"Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab","volume":"23","author":"Toi","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2021.08.036_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.ejca.2021.08.036_bib37","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.08.036_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2021.08.036_bib39","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors","volume":"22","author":"Judd","year":"2017","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.ejca.2021.08.036_bib40","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ejca.2021.08.036_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002421","article-title":"Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy","volume":"9","author":"Cortellini","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2021.08.036_bib42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","article-title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials","volume":"31","author":"Chalabi","year":"2020","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921005670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921005670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:36:22Z","timestamp":1760733382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921005670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":42,"alternative-id":["S0959804921005670"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.08.036","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.08.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}